About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Man Hands on Misery to Man | Main | How Not to Do It: Liquid Nitrogen Tanks »

March 8, 2006

Things Turn Nasty

Email This Entry

Posted by Derek

Back in 2003, I wrote about the excitement over PYY3-36, a peptide which showed some profound effects on feeding in animal models, but I wasn't exactly jumping up and down:

. . .You're not going to be able to take this orally. It's going to be i.v. or bust for some time, I'm afraid. There's some hope for taking peptides of this size nasally, although it's tricky, and there's an outside chance of getting them through via a transdermal patch, but I wouldn't bet on that one. . .And these are early days. The obesity field is cluttered up with promising ideas that have deflated. . .

A small company called Nastech took a whack at the idea, using the nasal delivery route, and they had some promising Phase I data. Well, OK, Phase I isn't designed to show efficacy, but they looked anyway, and saw some. In the eleven patients who completed the study, that is. Well, OK, in the nine responders. But the data were interesting enough to get Merck on board to fund some real efficacy studies.

Well, the results are in, and the headline says it all: "Nastech Pharmaceutical Company Reacquires PYY3-36 Nasal Spray. . ." is how the press release starts, and you know what that means. The stuff missed its endpoints most powerfully, and Merck hit it back over the net. Makes you wonder what the deal was with the positive human data that had been reported by others back in happier days, doesn't it?

Nastech makes what they can out of the blood levels they observed, and says that they hope to take the peptide back into Phase II once they've worked out a better dosing regimen. I wouldn't stand on one leg while waiting for that happen, but I wish them luck. There may be other indicators over the next few weeks or months. As Fred Cohen points out, Amylin is also working on the same peptide with an injectable dosing protocol, and if you see them pulling out of the field then that's going to be that.

Perhaps the saddest paragraph in the Nastech release is this one:

Nastech intends to cooperate with Merck in the production of a manuscript to be submitted for publication concerning the clinical trials performed by Merck. Merck noted that the 'interaction between Merck and Nastech has been positive and professional', and that they 'would welcome the opportunity to collaborate with Nastech again should the appropriate opportunity arise.' Nastech as well would welcome the opportunity to work with Merck in the future.

I'll bet that they would, and I hope that they get the chance. For now, it looks like this work is going to go to where drug development projects go when they die: publication in a peer-reviewed scientific journal. For industrial scientists, that's a sad way for things to end. The obesity field may have yet another failed hypothesis to deal with; you'd think that it already had ruined enough for anyone.

Comments (0) + TrackBacks (0) | Category:


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry